| Q37531862 | A new pharmacological role for donepezil: attenuation of morphine-induced tolerance and apoptosis in rat central nervous system |
| Q35027984 | Attenuation of tolerance to opioid-induced antinociception and protection against morphine-induced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. |
| Q39832543 | Cell-specific loss of kappa-opioid receptors in oligodendrocytes of the dysmyelinating jimpy mouse |
| Q28363748 | Chronic morphine induces up-regulation of the pro-apoptotic Fas receptor and down-regulation of the anti-apoptotic Bcl-2 oncoprotein in rat brain |
| Q41910089 | Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons |
| Q43680252 | Endogenous opioids and oligodendroglial function: possible autocrine/paracrine effects on cell survival and development |
| Q73544921 | Mechanisms of apoptosis in embryonic cortical neurons (E6 and E7) in culture involve lipid signalling, protein phosphorylation and caspase activation |
| Q36302053 | Molecular targets of opiate drug abuse in neuroAIDS. |
| Q43119443 | Opioids intrinsically inhibit the genesis of mouse cerebellar granule neuron precursors in vitro: differential impact of mu and delta receptor activation on proliferation and neurite elongation |
| Q22253392 | Palmitoyl protein thioesterase 1 protects against apoptosis mediated by Ras-Akt-caspase pathway in neuroblastoma cells |
| Q44332350 | Regulation of nonphosphorylated and phosphorylated forms of neurofilament proteins in the prefrontal cortex of human opioid addicts |
| Q28354326 | Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro |
| Q48385759 | The 5-HT1A receptor agonist BAY x 3702 prevents staurosporine-induced apoptosis |
| Q44248952 | The effect of opioid agonists of delta-class DSLET, mu-class DAMGO, kappa-class U-69593 and an opioid antagonist, naloxone, on MTT activity of NALM-1 leukemic cells |
| Q37804769 | The impact of the perioperative period on neurocognitive development, with a focus on pharmacological concerns |